Nucleozin
Nucleozin, a potent inhibitor of influenza A virus infection, induces the formation of nucleoprotein (NP) aggregates and antagonizes its nuclear accumulation, leading to cessation of viral replication. Nucleozin impedes influenza A virus replication in vitro with a nanomolar EC50[1].
Product Specifications
CAS Number
341001-38-5
UNSPSC
12352005
Hazard Statement
H301
Target
Influenza Virus
Type
Reference compound
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/Nucleozin.html
Purity
99.66
Solubility
DMSO : 20 mg/mL (ultrasonic)
Smiles
CC1=C(C(C2=CC=CC=C2)=NO1)C(N3CCN(C4=C(C=C(C=C4)[N+]([O-])=O)Cl)CC3)=O
Molecular Formula
C21H19ClN4O4
Molecular Weight
426.85
Precautions
H301
References & Citations
[1]Kao RY, et al. Identification of influenza A nucleoprotein as an antiviral target. Nat Biotechnol. 2010;28 (6) :600-605.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Recombinant Rat Arf-GAP with coiled-coil, ANK repeat and PH domain-containing protein 2 (Acap2)
Recombinant Rat Arf-GAP with coiled-coil, ANK repeat and PH domain-containing protein 2 (Acap2)
Recombinant Rat Arf-GAP with coiled-coil, ANK repeat and PH domain-containing protein 2 (Acap2)
Recombinant Rat Arf-GAP with coiled-coil, ANK repeat and PH domain-containing protein 2 (Acap2)